Navigation Links
NexCore Group Opens Chicago Office Recruits New Hires
Date:1/23/2008

of assets in 2007 including: Potomac Medical Plaza at The Medical Center of Aurora (TMCA HealthONE), Aurora, CO; two Memorial Healthcare System Medical Office Buildings (MOBs), Colorado Springs, CO; Broadway MOB at Saint Luke's Hospital, Kansas City, MO; AETNA/SRC Headquarters, Columbia, SC; three NorthBay Healthcare MOBs, Vacaville and Fairfield, CA., Green Valley Ranch MOB, Aurora, CO, and Holy Family Hospital MOB, Spokane, WA.

About NexCore Group

NexCore Group delivers comprehensive healthcare real estate solutions for hospitals, healthcare systems and physician partners across the U.S. NexCore and its principals have developed and acquired over 4.7 million square-feet of facilities and currently own and manage 1.4 million square-feet of healthcare and commercial real estate. NexCore is headquartered in Denver, with offices in Chicago and Baltimore.

Contact: Angela Barbosa, angela.barbosa@nexcoregroup.com, 303-244-0709.


'/>"/>
SOURCE NexCore Group
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Broad-based group of physicians calls for improvement in stroke treatment
2. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
3. CIGNA Group Insurance Shows Consumers Theres More to Life Through a New Consumer Education Toolkit
4. HIDA Calls for Scrutiny of Group Purchasing Organization Distributor Fee Structure
5. New Research Uncovers how to Build and Maintain an Effective Competitive Intelligence Group
6. AMERIGROUP to Acquire Memphis Health Plan
7. Securians Minnesota Life Continues to Climb Group Life Rankings
8. Dr. Allen Woolf Appointed Chief Medical Officer For CIGNA Group Insurance
9. Are Bargaining Groups Hired by Independent Drugstores Causing Payment Delays to Pharmacies?
10. Group B Strep: A Threat to Newborns That Doesnt Have to Be
11. Cynosure to Present at the Maxim Group Growth Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/5/2008)...ert Pathologists Discuss the Latest Developments i...RTHFIELD, Ill., Sept. 5 /PRNewswire-USNewswire/ --...point. Molecular testing and the promise,of person...reated. Digital,slides and other imaging technolog...lege of American Pathologists is taking a leadersh...
(Date:9/5/2008)...hers explain how theoretical ,anti-cloak, could br...pt. 5 (HealthDay News) -- Just in case someone dev...cientists say they know how to uncloak the objects... Optics Express , certain materials underneath an ...o be seen again. , Researchers at Shanghai Jiao...
(Date:9/5/2008)...HINGTON, Sept. 5 /PRNewswire-USNewswire/ -- Speake...y in support of the aims of the "Stand,Up to Cance... "There is not a person in our country who has no...r kills 565,000 Americans annually, and each,year ...ricans must work,together to make eradicating the ...
(Date:9/5/2008)...HINGTON, Sept. 5 /PRNewswire-USNewswire/ -- U.S. c...r relief to Cuban victims of Hurricane,Gustav, whi...s., (http://www.PanAmericanRelief.org ), "Donatio...perately need,after this natural disaster," says M... Initiative at the Pan American Development Founda...
Breaking Medicine News(10 mins):Health News:Leaders in Pathology Meet in San Diego: Sept. 25 - 28, 2008 2Health News:Cuban Disaster Relief Donations Sought in the Wake of Hurricane Gustav 2
...ogs have surprised researchers by showing that the...an toddlers. The study, by Austrian researchers,... when it comes to a physical problem-solving test....en researchers first observed how several children...
...tgrave, PhD, an expert on HIV prevention at the Jo...argeted campaign of testing and counseling aimed ...e effective than the mass patient screening propos...and Prevention (CDC). Holtgraves study is the fir...
...nday against South Korea's hard-drinking culture w...d economic losses, officials said . The campaign f...re to enhance public awareness of the dangers of e...ealth and Welfare said. "South Koreans consider o...
...heimer drug in the form of a milkshake. This milks...tarved by the damages of the Alzheimer disease . I...g large scale testing against the brain destroying...d Ketasyn, is a new approach to treating dementia....
Other Medicine News:Health News:Dogs Reasoning on Par With Human Toddlers: Study 2Health News:Targeted HIV Testing An Effective Way to Screen HIV Patients 2Health News:A Milky Alternative to Alzheimer Drug 2
(Date:9/3/2008)...Wrong Children Studied. Wrong,Conclusions Reached.... Centers for Disease,Control and Prevention (CDC) ...en the MMR vaccine and autism. The National Autism... dispel the growing public concern over a,vaccine-...cerning design,and methodology., For years, paren...
(Date:9/3/2008)...scular Disease Awareness Month, CHARLOTTESVILLE, ...cals,LLC, a clinical-stage drug-development compan...nmet medical needs, announced today that it has be...ial of its lead drug,candidate trans sodium crocet...the clinicaltrials.gov Website, is investigating T...
(Date:9/3/2008)... Phase 3 Plans with FDA, PRINCETON, N.J., Sept. 3...ed today that it successfully completed two key cl...new, innovative low-dose, once-weekly,contracepti...nal product,code AG-200-15. The Phase 2b safety an...oint of ovulation suppression, cycle control and s...
(Date:9/3/2008)...swire-FirstCall/ -- A sub-analysis of,the TRITON-T...rasugrel,compared with clopidogrel significantly r...(7.4 percent vs. 9.7 percent, p<0.0001), regardles...f an artery-opening,procedure known as percutaneou... spontaneously during the longer-term maintenance ...
Breaking Medicine Technology:CDC Misses Target With Flawed MMR/Autism Study 2Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 2Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 3Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 4Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch 2Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch 3Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch 4Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel 2Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel 3Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel 4Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel 5Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel 6Biannual Antibiotics May Cut Major Cause of Blindness in Africa 12290 1Biannual Antibiotics May Cut Major Cause of Blindness in Africa 12290 2NIST NCI SAIC partner on new method for detecting HER2 breast cancer 12288 1NIST NCI SAIC partner on new method for detecting HER2 breast cancer 12288 2DATATRAK International Management to Host Conference Call on February 26 2008 to Discuss Fourth Quarter and Full Year Operating Results for 2007 12285 1DATATRAK International Management to Host Conference Call on February 26 2008 to Discuss Fourth Quarter and Full Year Operating Results for 2007 12285 2DATATRAK International Management to Host Conference Call on February 26 2008 to Discuss Fourth Quarter and Full Year Operating Results for 2007 12285 3XTENT Announces 2007 Financial Results 12282 1XTENT Announces 2007 Financial Results 12282 2XTENT Announces 2007 Financial Results 12282 3XTENT Announces 2007 Financial Results 12282 4XTENT Announces 2007 Financial Results 12282 5XTENT Announces 2007 Financial Results 12282 6
....--(BUSINESS WIRE)--Apr 25, 2007 - BioDelivery,Sci... today,statistically significant results with BEMA... pain in its pivotal Phase III efficacy,clinical t...ievement of the primary efficacy endpoint of the t... compared to placebo., The results demonstrated th...
...mark; April 25, 2007 - Genmab A/S (CSE: GEN),annou...th,ofatumumab (HuMax-CD20™) in patients with...oral presentation at the 2007,Annual European Cong...n, which will include new results from the double-...umumab, along with data,from the previous interim ...
Other Medicine Technology:BDSI Announces Positive Phase III Clinical Trial Results for BEMA,Fentanyl 2BDSI Announces Positive Phase III Clinical Trial Results for BEMA,Fentanyl 3BDSI Announces Positive Phase III Clinical Trial Results for BEMA,Fentanyl 4BDSI Announces Positive Phase III Clinical Trial Results for BEMA,Fentanyl 5BDSI Announces Positive Phase III Clinical Trial Results for BEMA,Fentanyl 6
Tank Blotting System. Designed for Western, Northern, or Southern Blotting. Transfer up to three gels with dimensions as large as 15cm x 21.5cm. Includes and internal cooling base for temperature
... proven electrophoretic transfer apparatus incorpo...ltimate in field uniformity. Its design allows for... when coupled with a low voltage power source such...ts/cm. The result is exceptionally rapid and exact...
...lot cell, a component of Bio-Rad's modular mini el...resis Systems), provides rapid, high-quality blott...ransfers two 7.5 x 10 cm gels in just 1 hour. Cool... absorbs heat generated during transfers. The Mini...
Includes PowerPac 200 power supply. Flexibility for a Range of Parameters. Quantitative Transfers. Native Enzyme, High Intensity, or Overnight Transfers. Faster, Higher-Efficiency Transfers via Pl
Medicine Products: